We are live on ! Find out more
NVO icon

Novo Nordisk

1,484 hedge funds and large institutions have $21.3B invested in Novo Nordisk in 2025 Q2 according to their latest regulatory filings, with 128 funds opening new positions, 585 increasing their positions, 573 reducing their positions, and 160 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more repeat investments, than reductions

Existing positions increased: 585 | Existing positions reduced: 573

0% more funds holding in top 10

Funds holding in top 10: 25 → 25 (0)

0.36% less ownership

Funds ownership: 7.3% → 6.94% (-0.36%)

3% less funds holding

Funds holding: 1,532 → 1,484 (-48)

20% less first-time investments, than exits

New positions opened: 128 | Existing positions closed: 160

30% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.63B

33% less capital inflows, than outflows

Capital inflows: $2.11B | Capital outflows: $3.17B

Holders
1,484
Holders Change
-48
Holders Change %
-3.13%
% of All Funds
19.45%
Holding in Top 10
25
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.33%
New
128
Increased
585
Reduced
573
Closed
160
Calls
$1.14​B
Puts
$1.63​B
Net Calls
-⁠$491​M
Net Calls Change
-⁠$136​M

NVO Hedge Fund Activity: Q2 2025 in Review

1,484 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2025, worth a combined $21.3B — down 5.4% from $22.5B a quarter earlier.

Sellers outnumbered buyers: 160 funds closed out of NVO and 128 opened new positions — a net loss of 32 holders — while 573 trimmed existing stakes and 585 added.

The largest buyer was Fidelity Investments, adding an estimated $293M. The largest seller was Amundi, exiting entirely with an estimated $332M sold.

  • 1,484 institutional investors held Novo Nordisk (NVO) as of Q2 2025, down from 1,532 in Q1 2025.
  • Funds reported $21.3B of Novo Nordisk stock for Q2 2025, down 5.4% quarter-over-quarter.
  • 128 funds opened new Novo Nordisk positions in Q2 2025 and 160 closed out, a net change of -32 holders.
  • The largest Novo Nordisk buyer in Q2 2025 was Fidelity Investments, an estimated $293M added.
  • The largest Novo Nordisk seller in Q2 2025 was Amundi, an estimated $332M sold.

Based on aggregated 13F filings for Q2 2025.